Lab Information
Talat Bessissow (MD/MSc)
InvestigatorClinical Research Unit
Department of Medicine (McGill)
Research Profile
Keywords
Crohn's disease • ulcerative colitis • mucosal healing • neoplasia • pathogenesisResearch Interests
My research focuses on the role of mucosal healing in the treatment of inflammatory bowel diseases. I am also looking at identifying factor that predict disease relapse.Team Members
| Name | Position |
|---|
Latest Publications
- Farkas, B., Bessissow, T., Limdi, J. K., Sethi-Arora, K., Kagramanova, A., Knyazev, O., Bezzio, C., Armuzzi, A., Lukas, M., Michalopoulos, G., Chaskova, E., Savarino, E. V., Castiglione, F., Rispo, A., Schäfer, E., Saibeni, S., Filip, R., Attauabi, M., Fousekis, F. S., Bacsur, P., Resál, T., Bálint, A., Ivány, E., Szepes, Z., Bősze, Z., Fábián, A., Bor, R., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study. Journal of clinical medicine, vol. 13.
- Solitano, V., Narula, N., Ma, C., Nanayakkara, A., Suarez, K. E., Zoughlami, A., Guizzetti, L., Bessissow, T. & Jairath, V. (2024). Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study. The American journal of gastroenterology.
- Di Fonzo, D. M. P., Alabdulkarim, B., Yanofsky, R., Abduallah, Y., Golovics, P., Lakatos, P. L., Bitton, A., Wild, G., Afif, W. & Bessissow, T. (2024). Association Between Serum Ustekinumab Concentrations and Endoscopic Disease Activity in Moderate-to-Severe Crohn's Disease Patients. Crohn's & colitis 360, vol. 6, p. otae071.
- Abbas, A., Di Fonzo, D. M. P., Wetwittayakhlang, P., Al-Jabri, R., Lakatos, P. L. & Bessissow, T. (2024). Management of ulcerative colitis: where are we at and where are we heading?. Expert review of gastroenterology & hepatology, p. 1-8.
- Bacsur, P., Resál, T., Sarlós, P., Iliás, Á., Dalma Sümegi, L., Kata, D., Dávid, A., Farkas, B., Ivány, E., Bálint, A., Bősze, Z., Fábián, A., Bor, R., Szepes, Z., Afif, W., Bessissow, T., Farkas, K., Lakatos, P. L. & Molnár, T. (2024). Outcomes of treatment cessation after switching to subcutaneous vedolizumab treatment in inflammatory bowel diseases. Therapeutic advances in gastroenterology, vol. 17, p. 17562848241290636.
- Shehab, M. & Bessissow, T. (2024). Editorial: Advancing care in Crohn's disease-Time to standardise bowel preparation scales. Alimentary pharmacology & therapeutics, vol. 60, p. 1455-1456.
- Shehab, M., Alrashed, F., Alsayegh, A., Aldallal, U., Ma, C., Narula, N., Jairath, V., Singh, S. & Bessissow, T. (2024). Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
- Shehab, M., Hassan, A., Alrashed, F., Abbas, A., Ma, C., Narula, N., Jairath, V., Singh, S. & Bessissow, T. (2024). Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Inflammatory bowel diseases.
- Shehab, M., De Marco, D., Lakatos, P. L. & Bessissow, T. (2024). The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review. Expert opinion on biological therapy, p. 1-14.
- Wetwittayakhlang, P., Kotrri, G., Bessissow, T. & Lakatos, P. L. (2024). How close are we to a success stratification tool for improving biological therapy in ulcerative colitis?. Expert opinion on biological therapy, p. 1-9.
See also
